Next Generation Antibody Therapeutics: From Discovery to Patient

下一代抗体疗法：从发现到患者

• 批准号: 10540498
• 负责人: TERRY L. SHEPPARD
• 金额: $ 1.44万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10540498
• 关键词: Academia; Address; Antibodies; Antibody Therapy; Area; Autoimmune Diseases; Autoimmunity; Automobile Driving; Biological Process; British Columbia; Canada; Cells; Clinical; Collaborations; Communicable Diseases; Development; Disease; Educational workshop; Environment; Event; Future; Generations; Growth and Development function; Immune; Industry; Inflammation; Knowledge; Learning; Malignant Neoplasms; Methodology; Methods; Mind; Modality; Monoclonal Antibody Therapy; Oncology; Outcome; Participant; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Postdoctoral Fellow; Property; Protein Engineering; Research; Research Personnel; Scientist; Students; Technology; Therapeutic; Therapeutic antibodies; Time Management; Translating; Validation; antibody engineering; base; bench to bedside; cancer immunotherapy; career; clinical practice; cost; design; drug development; drug discovery; human disease; improved; insight; interest; learning network; meetings; multidisciplinary; next generation; novel; novel drug class; novel strategies; posters; programs; symposium; therapeutic development; therapy development

ABSTRACT Support is requested for a Keystone Symposia conference entitled Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Drs. Pamela Holland and James Wells. The conference will be held in Banff, British Columbia, Canada, from February 19-22, 2023. Therapeutic antibodies have become the predominant class of new drugs gaining FDA approval and are the best-selling drugs in the pharmaceutical market for treating various human diseases, including cancer, autoimmune, and infectious diseases. Over the past 30 years, major technological advances have facilitated the discovery and development of monoclonal antibody therapies, and new strategies are continually emerging to enhance their clinical potential. Though substantial progress has been made, new opportunities and challenges continue to evolve in this rapidly moving field. Multiple advances in antibody technology to expand antibody attributes have already translated into improved clinical activity in multiple therapeutic areas. Yet they also unveil major challenges with respect to target validation, method of action, protein design, development time, and managing increasing costs of antibody manufacturing. This conference will provide a diverse program comprised of academic and industry scientists that addresses the challenges and opportunities relevant to antibody drug discovery and development. Furthermore, it will include sessions which focus on target identification and novel discovery platforms, as well as advances in protein engineering to improve functional properties and new antibody modalities and delivery methods. There will also be topics that will provide an overview of emerging clinical therapeutics in oncology, infectious disease and autoimmunity/inflammation. Overall, this program will offer investigators a perspective on the full spectrum of antibody therapeutic development from bench to bedside and will highlight cutting edge technological and clinical advancements of interest to a broad spectrum of scientists. Finally, this conference is being paired with another Keystone Symposia meeting on Multispecific Immune Cell Engagers for Cancer Immunotherapy. This will allow participants at both conferences the chance to network and develop new collaborations through shared sessions and meals. The conference will provide a stimulating environment where students, postdocs and junior investigators can present and discuss their research with the best minds in the field.

抽象的 请求支持Keystone研讨会会议，标题为“下一代抗体疗法： 从发现到患者，由Drs组织。帕梅拉·荷兰（Pamela Holland）和詹姆斯·威尔斯（James Wells）。会议将举行 从2023年2月19日至22日，在加拿大不列颠哥伦比亚省的班夫。 治疗性抗体已成为获得FDA批准的新药的主要类别，并且是 在药物市场中最畅销的药物治疗各种人类疾病，包括癌症， 自身免疫和传染病。在过去的30年中，主要的技术进步促进了 单克隆抗体疗法的发现和开发以及新策略不断出现 增强其临床潜力。尽管已经取得了重大进展，但新的机会和 在这个快速移动的领域中，挑战继续发展。抗体技术的多重进步以扩展 抗体属性已经转化为多种治疗区域的临床活性。但是他们 还针对目标验证，作用方法，蛋白质设计，开发提出了重大挑战 时间，并管理抗体制造成本增加。这次会议将提供多种多样的 计划由学术和行业科学家组成，这些科学家应对挑战和机遇 与抗体药物发现和开发有关。此外，它将包括关注的会议 目标识别和新颖的发现平台，以及蛋白质工程的进步以改进 功能性能和新抗体方式和递送方法。也将有一些主题 提供肿瘤学，传染病和 自身免疫/炎症。总体而言，该计划将为调查人员提供有关完整范围的观点 抗体的治疗性开发从长凳到床边，将突出尖端技术和 广泛的科学家感兴趣的临床进步。最后，这次会议与 另一场有关癌症免疫疗法多特异性免疫细胞招聘的Keystone研讨会会议。这 这两个会议的参与者都有机会通过 共同的会议和餐点。会议将提供一个刺激的环境，学生，博士后 初级调查人员可以与该领域的最佳思想展示和讨论他们的研究。